R. Delva

发表

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.

A. Ravaud, B. Melichar, A. Santoro, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer

F. Penault-Llorca, M. Mouret-Reynier, P. Chollet, 2006, Breast Cancer Research and Treatment.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

S. Culine, G. Gravis, N. Houédé, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

S. Culine, Y. Allory, S. Oudard, 2019, Clinical genitourinary cancer.

Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.

F. Penault-Llorca, I. van Praagh, C. Abrial, 2005, The oncologist.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

F. Penault-Llorca, M. Mouret-Reynier, P. Chollet, 2005, Breast Cancer Research and Treatment.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

B. Weber, O. Trédan, S. Touzet, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers

F. Penault-Llorca, M. Mouret-Reynier, C. Abrial, 2005, Medical Oncology.

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

F. Penault-Llorca, M. Mouret-Reynier, P. Chollet, 2006, Clinical breast cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.

S. Foulon, S. Ladoire, Y. Neuzillet, 2023, European urology.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012 .

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.